



“Molecular Modeling, Synthesis and Anticancer Activity of Fused Triazine Derivatives”

Thesis

Presented by

Khulood Hayal Oudah

BSc. In Pharmaceutical Sciences(2002)

College of Pharmacy, Mosul University

Submitted for the partial fulfillment of the

Master Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

Under the supervision of

Prof. Dr. / Khaled A. M. Abouzid

Professor of Pharmaceutical Chemistry &

Head of the Pharmaceutical Chemistry Department

Faculty of Pharmacy- Ain Shams University

Dr. / Rabah A. Taha Serya

Assistant Professor of Pharmaceutical Chemistry

Faculty of Pharmacy- Ain Shams University

Dr. / Nermin Samir Abdou

Lecturer of Pharmaceutical Chemistry

Faculty of Pharmacy- Ain Shams University

Faculty of pharmacy

Ain Shams University

2017

Acknowledgements

Thanks to **Almighty Allah** for giving me strength and ability to understand, learn and complete this work.

First and foremost I would like to express my deepest sense of gratitude to **Professor Dr. Khaled Abouzid**, Professor of Pharmaceutical Chemistry and Head of the Pharmaceutical Chemistry Department, who has the attitude and the substance of genius. I am sincerely grateful to his devotion to his students' education and success. The door of Dr. Khaled's office was always opened whenever I ran into a trouble spot or had a question about my research. He was the one who taught me how to be multitasking. I owe him a huge debt of gratitude for his guidance, endless support and immense knowledge.

I owe deep appreciation and truthful gratitude to **Dr. Rabah Ahmed Taha Serya**, Associate Professor of Pharmaceutical Chemistry, for her kindness, continuous encouragement, indispensable assistance, valuable guidance and constant support throughout the whole work.

It is my genuine pleasure to express my heartiest thanks to **Dr. Nermin Samir**, lecturer in pharmaceutical Chemistry, for her fruitful opinion, untiring help, valuable assistance and constant encouragement during writing this thesis.

I acknowledge with thankfulness all my friends in Pharmaceutical Chemistry Department, for their friendly cooperation, support and their unconditional love and aid.

Also I would like to express my gratitude to the National Cancer Institute, Maryland, U.S.A for performing the cytotoxicity assay of the synthesized compounds.

Finally, I am profoundly indebted to my parents, my beloved husband, and my little kids for their unconditional love and aid, endless patience, understanding, encouragement and full support all throughout the whole long way.



*This dissertation is dedicated to the late **prof. Dr. Mohamed Abd Elhamid Ismail** whose passion for teaching set a new standard for anyone involved in education, research and supervision or any other endeavor in which one seeks to support the development of another. His versatile knowledge in pharmaceutical chemistry and drug design and his unique teaching style has developed our knowledge and cleared many ambiguities. I am so grateful to him for assisting this challenging dissertation. Finally I would like to express my deepest gratitude to his vision and foresight which inspired me to conceive this thesis.*

May Allah Bless His Soul

General and special postgraduate courses in Pharmaceutical Chemistry

Besides the work presented in this thesis, the candidate successfully passed general and special postgraduate courses in Pharmaceutical Chemistry for one year during academic year 2014/2015 with the general grade Very good as following:

1. Instrumental Analysis	Very Good
2. Physical Chemistry	Passed
3. Computer Sciences	Excellent
4. Statistics	Good
5. Pharmaceutical Chemistry	Excellent
6. Drug Stereochemistry	Excellent
7. Drug Spectroscopy	Good
8. Selected Topics in Pharmaceutical Chemistry	Good

Table of contents:

<i>Acknowledgements</i>	I
<i>General and special postgraduate courses in Pharmaceutical Chemistry</i>	III
<i>Table of contents</i>	IV
<i>List of Figures</i>	VII
<i>List of Tables</i>	IX
<i>List of Abbreviations</i>	X
<i>Abstract</i>	XII
1. Introduction	1
1.1. Cancer.....	1
1.1.1. Overview.....	1
1.1.2. Development.....	1
1.1.3. Hallmarks of cancer.....	3
1.1.4. Etiology and carcinogenic factors.....	4
1.1.5. Epidemiology.....	5
1.1.6. Treatment.....	5
1.2. Protein kinases as cancer targeted therapy.....	13
1.2.1. Overview on Protein kinases.....	13
1.2.2. Cyclin-Dependent Kinases	13
1.2.3. Role of Cyclin-Dependent Kinases in cell cycle	14
1.2.4. The structure of Cyclin2-dependent kinases and its activation.....	16
1.2.5. CDK2 inhibitors as important target in cancer therapy	18
1.2.6. Strategies in developing cyclin-dependent kinase2 Inhibitors	18

2. Rationale and Design.....	29
2.1. Consideration of the previously explored SAR and determination of the key interactions between the binding site and ATP competitive inhibitor.....	30
2.2. Design of novel pyrazolo(1,5-a)(1,3,5)triazine based CDK2 inhibitors.....	33
2.3. Primary evaluation of some selected compounds by using Molecular docking	36
2.4. Synthetic schemes for synthesis of the designed compounds.....	39
2.4.1 Scheme (1): preparation of Ethyl 2-(ethylthio)-4-substituted phenylpyrazolo [1,5-a][1,3,5] triazine-8-carboxylate (VIIIa-c).....	40
2.4.2 Scheme (2): preparation of compounds (IXa-o) & (Xa-c).....	41
3. Results and Discussion.....	42
3.1. Chemistry.....	42
3.1.1. Scheme 1.....	42
3.1.2. Scheme 2.....	49
3.2. Biological Evaluation.....	52
3.2.1. <i>In vitro</i> CDK2/CyclinA2 Kinase inhibitory Activity.....	52
3.2.2. <i>In vitro</i> antiproliferative activity against NCI 60-cell line	56
3.2.3 <i>In vitro</i> cytotoxic activity against MCF-7 cancer cell lines.....	66
3.3. Molecular modeling study.....	67
3.3.1. Docking study	67
3.3.2. In silico ADMET study.....	77
4. Conclusion.....	80
5. Experimental.....	82
5.1. Chemistry.....	82
5.1.1. Materials and instrumentation.....	82

Table of contents

5.1.2. Synthesis.....	83
5.2. Biological evaluation.....	103
5.2.1. In vitro CDK2/CyclinA activity	103
5.2.2. In vitro Anti-proliferative activity against 60 cell line panel	104
5.2.3. In vitro cytotoxic activity against MCF-7 cancer cell lines.....	105
5.3. Molecular docking study.....	106
5.3.1. Protein preparation for docking.....	106
5.3.2. Ligand preparation for docking.....	106
5.2.3. Docking process.....	106
6. Supplementary Data.....	108
7. References.....	129

List of figures:

Figure 1: Three- phase process of carcinogenesis.....	2
Figure 2: The Hallmarks of Cancer.....	3
Figure 3: Milestones in the identification of the cell cycle	14
Figure 4: Cycline-dependent kinase function in cell-cycle	15
Figure 5: Structure biology of cyclin-dependent kinase 2- cyclin A	17
Figure 6: Strategies for targeting Cyclin-dependent kinases	18
Figure 7: Exploiting the CDK2–ANS interaction to identify small-molecule ligands.....	27
Figure 8: Pharmacophoric model of kinase active site (ATP binding site)	30
Figure 9: A selection of protein kinase inhibitors for which CDK2/inhibitor structures have been determined	32
Figure 10: Reported binding mode of lead compound roscovitine (28) with CDK2/cyclin A.	33
Figure11: Design of novel CDK2 inhibitors based on Roscovitine (28) lead compound	35
Figure 12: Mechanism of cyclization of 5-aminopyrazole	43
Figure 13: Synthesis of pyrazolo[1,5-a][1,3,5]triazine through two-bond cyclization.....	46
Figure 14: Synthesis of 4-amino-2-methyl-7-phenylpyrazolo[1,5-a][1,3,5]triazine through two-bond cyclization.....	46
Figure 15: Synthesis of 7-oxo-4-thioxopyrazolo[1,5-a][1,3,5]triazine.....	46

Figure 16: Pyrazolo[1,5-a][1,3,5]triazine scaffold generated by transformation of the 1,3,5-thiadiazine ring.....	47
Figure 17: Mechanism of synthesis of ethyl 2-(ethylthio)-4-substituted phenylpyrazolo [1,5- <i>a</i>] [1,3,5]triazine-8 carboxylate (VIIIa-c).....	48
Figure 18: Structure of NCI selected compounds.....	57
Figure 19: Example of mean graph produced from NCI 60 cell lines screening program. Mean graph of compound (IXl) colour code are given for each cell line.....	58
Figure 20: %Inhibition of compound IXl against (26 cell line from 56 NCI cell line) that exhibit % inhibition range from (40%-115%).....	63
Figure 21: % inhibition of compound Xc against (17 cell line from 56 NCI cell line) that exhibit % inhibition range from (43%-92%).....	64
Figure 22: % Inhibition of compound IXg against (9 cell line from 56 NCI cell line) that exhibit % inhibition range from (42%-81%).....	65

List of Tables:

Table 1. Docking energy and amino acid involved in the binding interactions of some of the designed compounds with compared with Roscovitine (28). (PDB code 3ddq).....	36
Table 2. percentage inhibition of CDK2 enzymatic activity showed by compounds VIII (a-c)	52
Table 3. Percentage inhibition of CDK2 enzymatic activity showed by compounds IX (a-o)	53
Table 4. Percentage inhibition of CDK2 enzymatic activity showed by compounds X (a-c)	54
Table 5. The IC ₅₀ value for compounds (IXg, IXh, IXk, IXl, IXm, Xa and Xc).....	56
Table 6. Cell growth percentage of NCI 60 cancer cell lines exhibited by some of the investigated final compounds (VIIIa, VIIIc, IXb, IXg, IXh, and IXk).....	59
Table 7. Cell growth percentage of NCI 60 cancer cell lines exhibited by some of the investigated final compounds (IXl, IXm, IXn, IXo, Xa and Xc).....	61
Table 8. Cytotoxic activity of the remaining compounds against MCF-7 cancer cell lines.....	66
Table 9. Molecular docking investigation study of synthesized compounds in CDK2 active site (PDB code 3ddq) compared to Roscovitine (28).....	70
Table 10. Computer aided ADMET screening of the synthesized compounds.....	78

List of Abbreviations

2D: Two-dimensional

3D: Three-dimensional

Å: Angstroms

ADMET: absorption, distribution, metabolism, excretion and toxicity study

ATP: Adenosine triphosphate

CAK: CDK-Activated kinase

CDK: Cycline dependent kinase

CDKI: Cycline dependent kinase inhibitors

CDOCKER: CHARMM-based DOCKER

CHARMm: Chemistry at HARvard macromolecular mechanics

CIP: CDK interacting protein

DCM: Dichloromethane

DMF: Dimethyl formamide

DNA: Deoxyribonucleic acid

EGFR: Epidermal growth factor receptor

ELISA: Enzyme-linked ImmunoSorbent Assay

FDA: Food and Drug Administration

FT-IR: Fourier transform-Infrared

HAKRRLIF: Histidine, Alanine, Lysine, Arginine, Arginine, Leucine, Isoleucine, Phenylalanine

H-bond: hydrogen bond

Hr.: Hour

Hz: Hertz

IC₅₀: Half Maximal inhibitory concentration

INK4: Inhibitor of Kinase 4

kDa: unified atomic mass unit (symbol: u) or dalton (symbol: Da)

KIP: Kinase inhibitory protein

MD: Molecular dynamics

MHz: Mega hertz